PharmaMar announced today that its Investigational New Drug application (IND) has been accepted by the US Food and Drug Administration (FDA) for the clinical testing of Zalypsis® (PM00104/50), PharmaMar’s novel marine anti-tumour agent.
PharmaMar announced today that its Investigational New Drug application (IND) has been accepted by the US Food and Drug Administration (FDA) for the clinical testing of Zalypsis® (PM00104/50), PharmaMar’s novel marine anti-tumour agent.
